THEOPHYL-225 (theophylline) by Johnson & Johnson is clinical pharmacology mechanism of action: theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i. Approved for the symptoms, reversible airflow obstruction associated with chronic asthma, other chronic lung diseases and 1 more indications. First approved in 1981.
Drug data last refreshed 1w ago
CLINICAL PHARMACOLOGY Mechanism of Action: Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator prophylactic effects). While…
Worked on THEOPHYL-225 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Theophylline for Depression Study
Drug Interaction Study of Colchicine and Theophylline
A Study of LY2216684 and Theophylline in Healthy Subjects
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
Rosiglitazone Versus Theophylline in Asthmatic Smokers